
Hospitals Back Generic Drug Production Venture
More than 120 healthcare organizations plan to bring competition to generic drug market.
In an effort to ensure access to certain widely used drugs at affordable prices, a group of leading hospitals and health systems have established a
An initial proposal for a provider-based system to counter rocketing drug prices and serious shortages was announced in
The plan is to initially produce 14 hospital-administered generic drugs through contract manufacturers or generic drug makers with FDA-approved facilities, with the aim of bringing an initial product to market by early 2019. Van Trieste, who had recently retired and is heading the venture with no salary, expects the venture to bring “much needed competition to the generic drug market.”
An unknown is how current manufacturers will respond to this operation, perhaps by reducing prices or boosting production. Many short-supply therapies are sterile injectables, which raise production challenges. But hospitals anticipate that access to more reliable supplies will be important in reducing the time and effort now needed to track supplies, seek out alternatives, and advise health workers on the need to vary prescribing and drug administration practices.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.